Everolimus (RAD001): First Systemic Treatment for Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex

• Osborne JP , FryerA, WebbD. Epidemiology of tuberous sclerosis.Ann. N. Y. Acad. Sci.615, 125–127 (1991).
   PubMedGoogle Scholar
• Franz DN , BisslerJJ, McCormackFX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations.Neuropediatrics41, 199–208 (2010).
   PubMed Web of Science ®Google Scholar
• Schwartz RA , FernandezG, KotulskaK, JozwiakS. Tuberous sclerosis complex: advances in diagnosis, genetics, and management.J. Am. Acad. Dermatol.57, 189–202 (2007).
   PubMed Web of Science ®Google Scholar
• Curatolo P , BombardieriR, JozwiakS. Tuberous sclerosis.Lancet372, 657–668 (2008).
   PubMed Web of Science ®Google Scholar
• Borkowska J , SchwartzRA, KotulskaK, JozwiakS. Tuberous sclerosis complex: tumors and tumorigenesis.Int. J. Dermatol.50, 13–20 (2011).
   PubMed Web of Science ®Google Scholar
• Roach ES , GomezMR, NorthrupH. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria.J. Child. Neurol.13, 624–628 (1998).
   PubMed Web of Science ®Google Scholar
• Jozwiak S , SchwartzRA, JannigerCK, Bielicka-CymermanJ. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients.J. Child. Neurol.15, 652–659 (2000).
   PubMed Web of Science ®Google Scholar
• Goh S , ButlerW, ThieleEA. Subependymal giant cell tumors in tuberous sclerosis complex.Neurology63, 1457–1461 (2004).
   PubMed Web of Science ®Google Scholar
• Buccoliero AM , FranchiA, CastiglioneFet al. Subependymal giant cell astrocytoma (SEGA): is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study. Neuropathology 29, 25–30 (2009).
   PubMed Web of Science ®Google Scholar
• Cuccia V , ZuccaroG, SosaF, MongesJ, LubieniekyF, TaratutoAL. Subependymal giant cell astrocytoma in children with tuberous sclerosis.Childs Nerv. Syst.19, 232–243 (2003).
   PubMed Web of Science ®Google Scholar
• Adriaensen ME , Schaefer-ProkopCM, StijnenT, DuyndamDA, ZonnenbergBA, ProkopM. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature.Eur. J. Neurol.16, 691–696 (2009).
   PubMed Web of Science ®Google Scholar
• Grajkowska W , KotulskaK, JurkiewiczEet al. Subependymal giant cell astrocytomas with atypical histological features mimicking malignant gliomas. Folia Neuropathol. 49, 39–46 (2011).
   PubMed Web of Science ®Google Scholar
• Sancak O , NellistM, GoedbloedMet al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in tuberous sclerosis complex. Eur. J. Hum. Genet. 13, 731–741 (2005).
   PubMed Web of Science ®Google Scholar
• Huang J , ManningBD. The TSC1–TSC2 complex: a molecular switchboard controlling cell growth.Biochem. J.412, 179–190 (2008).
   PubMed Web of Science ®Google Scholar
• Kandt RS , HainesJL, SmithMet al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat. Genet. 2, 37–41 (1992).
   PubMed Web of Science ®Google Scholar
• van Slegtenhorst M , de HoogtR, HermansCet al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 277, 805–808 (1997).
   PubMed Web of Science ®Google Scholar
• European Chromosome 16 Tuberous Sclerosis Consortium: identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305–1315 (1993).
   PubMed Web of Science ®Google Scholar
• Jozwiak J , JozwiakS, WlodarskiP. Possible mechanisms of disease development in tuberous sclerosis.Lancet Oncol.9, 73–79 (2008).
   PubMed Web of Science ®Google Scholar
• Jozwiak S , KwiatkowskiD, KotulskaKet al. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis. J. Child. Neurol. 19, 102–106 (2004).
   PubMed Web of Science ®Google Scholar
• Roszkowski M , DrabikK, BarszczS, JozwiakS. Surgical treatment of intraventricular tumors associated with tuberous sclerosis.Childs Nerv. Syst.11, 335–339 (1995).
   PubMed Web of Science ®Google Scholar
• Ekici MA , KumandasS, PerHet al. Surgical timing of the subependymal giant cell astrocytoma (SEGA) with the patients of tuberous sclerosis complex. Turk. Neurosurg. 21, 315–324 (2011).
   PubMed Web of Science ®Google Scholar
• Sun P , KohrmanM, LiuJ, GuoA, RogerioJ, KruegerD. Outcomes of resecting subependymal giant cell astrocytoma (SEGA) among patients with SEGA-related tuberous sclerosis complex: a national claims database analysis.Curr. Med. Res. Opin.28, 657–663 (2012).
   PubMed Web of Science ®Google Scholar
• Sun P , KruegerD, LiuJ, GuoA, RogerioJ, KohrmanM. Surgical resection of subependymal giant cell astrocytomas (SEGAs) and changes in SEGA-related conditions: a US national claims database study.Curr. Med. Res. Opin.28, 651–656 (2012).
   PubMed Web of Science ®Google Scholar
• Franz DN , LeonardJ, TudorCet al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490–498 (2006).
   PubMed Web of Science ®Google Scholar
• Koenig MK , ButlerIJ, NorthrupH. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex.J. Child. Neurol.23, 1238–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Jozwiak J , JozwiakS, OldakM. Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment.Med. Res. Rev.26, 160–180 (2006).
   PubMed Web of Science ®Google Scholar
• Afinitor (everolimus) tablets for oral administration, prescribing information. Novartis Pharmaceuticals Corporation, NJ, USA (2012).
   Google Scholar
• Lebwohl D , ThomasG, LaneHAet al. Research and innovation in the development of everolimus for oncology. Expert Opin. Drug Discov. 6, 323–338 (2011).
   PubMed Web of Science ®Google Scholar
• Kirchner GI , Meier-WiedenbachI, MannsMP. Clinical pharmacokinetics of everolimus.Clin. Pharmacokinet.43, 83–95 (2004).
   PubMed Web of Science ®Google Scholar
• Benjamin D , ColombiM, MoroniC, HallMN. Rapamycin passes the torch: a new generation of mTOR inhibitors.Nat. Rev. Drug Discov.10, 868–880 (2011).
   PubMed Web of Science ®Google Scholar
• Kovarik JM , HartmannS, FigueiredoJ, RouillyM, PortA, RordorfC. Effect of rifampin on apparent clearance of everolimus.Ann. Pharmacother.36, 981–985 (2002).
   PubMed Web of Science ®Google Scholar
• Crowe A , BruelisauerA, DuerrL, GuntzP, LemaireM. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.Drug Metab. Dispos.27, 627–632 (1999).
   PubMed Web of Science ®Google Scholar
• O’Reilly T , McSheehyPM. Biomarker development for the clinical activity of the mTOR inhibitor everolimus (RAD001): processes, limitations, and further proposals.Transl. Oncol.3, 65–79 (2010).
   PubMed Web of Science ®Google Scholar
• Lane HA , WoodJM, McSheehyPMJet al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin. Cancer Res. 15, 1612–1622 (2009).
   PubMed Web of Science ®Google Scholar
• Beuvink I , BoulayA, FumagalliSet al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747–759 (2005).
   PubMed Web of Science ®Google Scholar
• Tanaka C , O’ReillyT, KovarikJMet al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J. Clin. Oncol. 26, 1596–1602 (2008).
   PubMedGoogle Scholar
• Meikle L , PollizziK, EgnorAet al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422–5432 (2008).
   PubMed Web of Science ®Google Scholar
• Pollizzi K , Malinowska-KolodziejI, StummM, LaneH, KwiatkowskiD. Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis.Mol. Cancer8, 38 (2009).
   PubMed Web of Science ®Google Scholar
• Boulay A , Zumstein-MeckerS, StephanCet al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 64, 252–261 (2004).
   PubMed Web of Science ®Google Scholar
• Krueger DA , CareMM, HollandKet al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363, 1801–1811 (2010).
   PubMed Web of Science ®Google Scholar
• Tillema JM , LeachJL, KruegerDA, FranzDN. Everolimus alters white matter diffusion in tuberous sclerosis complex.Neurology78, 526–531 (2012).
   PubMed Web of Science ®Google Scholar
• Jozwiak S . Everolimus in the treatment of subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis complex (TSC): the EXIST-1 trial. Presented at:The 12th International Child Neurology Congress and the 11th Asian and Oceanic Congress of Child Neurology Brisbane, Australia, 27 May–1 June 2012.
   Google Scholar
• Yalon M , Ben-SiraL, ConstantiniS, TorenA. Regression of subependymal giant cell astrocytomas with RAD001 (everolimus) in tuberous sclerosis complex.Childs Nerv. Syst.27, 179–181 (2011).
   PubMed Web of Science ®Google Scholar
• Perek-Polnik M , JozwiakS, JurkiewiczE, PerekD, KotulskaK. Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex.Eur. J. Paediatr. Neurol.16, 83–85 (2012).
   PubMed Web of Science ®Google Scholar
• Krueger DA , CareMM, HollandKet al. Long-term safety and efficacy results from an extension phase of an open-label, prospective, Phase 1/2 trial of oral everolimus in patients with subependymal giant cell astrocytomas in tuberous sclerosis complex. Presented at: The 16th Annual Scientific Meeting of the Society for Neuro Oncology CA, USA, 18–20 November 2011.
   Google Scholar
• Braun M , YoungJ, ReinerCS, PosterD, WuthrichRP, SerraAL. Ovarian toxicity from sirolimus.N. Engl. J. Med.366, 1062–1064 (2012).
   PubMed Web of Science ®Google Scholar
• Fritsche L , BuddeK, DragunD, EineckeG, DiekmannF, NeumayerHH. Testosterone concentrations and sirolimus in male renal transplant patients.Am. J. Transplant.4, 130–131 (2004).
   PubMed Web of Science ®Google Scholar
• Huyghe E , ZairiA, NohraJ, KamarN, PlanteP, RostaingL. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.Transpl. Int.20, 305–311 (2007).
   PubMed Web of Science ®Google Scholar
• Votubia 2.5 mg tablets, prescribing information. Novartis Europharm Limited, West Sussex, UK (2012).
   Google Scholar
• Afinitor summary of product characteristics, prescribing information. Novartis Europharm Limited, West Sussex, UK (2011).
   Google Scholar

Websites

• Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex. http://clinicaltrials.gov/ct2/show/NCT00411619?term=NCT00411619&rank=1
   Google Scholar
• Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1). http://clinicaltrials.gov/ct2/show/NCT00789828?term=NCT00789828&rank=1
   Google Scholar